Catalog No.
Product Name
Application
Product Information
Citations
-
MAO-B Inhibitor
MAO-B-IN-52 is a potent inhibitor of monoamine oxidase B (MAO-B), exhibiting an IC50 value of 83.7 μM. This compound demonstrates significant antioxidant activity, making it a valuable tool for research into neurodegenerative conditions such as Alzheimer's disease. Its targeting of MAO-B may provide insights into potential therapeutic strategies for modulating neuroinflammatory processes and oxidative stress. -
MAO-A Inhibitor
Moclobemide N-Oxide is an N-oxide metabolite of Moclobemide that primarily acts as a monoamine oxidase A (MAO-A) inhibitor. This compound exhibits inhibitory activity towards MAO-A, albeit typically at lower concentrations. It can be quantified through UV absorption at 240 nm, making it a valuable tool for studying the mechanisms of MAO-A inhibition in chemical research and pharmacological applications. -
MAO-B Inhibitor
MAO-B-IN-6 is a potent and selective inhibitor of monoamine oxidase B (MAO-B), exhibiting an IC50 value of 0.019 µM. This compound demonstrates superior efficacy compared to Safinamide in both in vitro and in vivo assays. MAO-B-IN-6 holds promise for advancing research in the pathophysiology and treatment of Parkinson's disease (PD). -
MAO-B Inhibitor
Milacemide hydrochloride is an orally active inhibitor of monoamine oxidase B (MAO-B) and a glycinamide derivative with demonstrated anticonvulsant properties. This compound effectively modulates neurotransmitter levels by decreasing dihydroxyphenylacetic acid and homovanilic acid while enhancing dopamine and serotonin concentrations in the caudate nucleus. Milacemide hydrochloride shows potential for investigation in Alzheimer's disease research and related neurodegenerative disorders. -
MAO-B Inhibitor
MAO-B-IN-30 is a selective inhibitor of monoamine oxidase B (MAO-B) that effectively crosses the blood-brain barrier, with IC50 values of 19.176 µM for MAO-A and 0.082 µM for MAO-B. This compound exhibits significant antiproliferative activity while demonstrating non-cytotoxic effects. Additionally, MAO-B-IN-30 effectively reduces pro-inflammatory cytokines, including TNF-alpha and IL-6, as well as the NF-kB pathway. Its properties make it a valuable tool for research into the mechanisms underlying Parkinson's disease. -
MAO-B Inhibitor
Monoamine Oxidase B inhibitor 5 is a selective and reversible inhibitor of monoamine oxidase B (hMAO-B) with an IC50 of 67.3 nM and a Ki value of 82.5 nM. This compound demonstrates favorable pharmacokinetic properties and low toxicity in rat models. Additionally, Monoamine Oxidase B inhibitor 5 has shown efficacy in alleviating MPTP-induced motor impairment in Parkinson’s disease mouse models, with the capability to cross the blood-brain barrier. This makes it a valuable tool for research in neurodegenerative diseases and MAO-B related pathways. -
Soybean Lipoxygenase Inhibitor
Methyl 9-hydroxyoctadeca-10,12,15-trienoate is a potent inhibitor of soybean lipoxygenase (LOX), which plays a critical role in the metabolism of arachidonic acid to leukotrienes. This compound has demonstrated significant anti-inflammatory activity by effectively inhibiting TPA-induced ear edema in murine models. Methyl 9-hydroxyoctadeca-10,12,15-trienoate is valuable for research in inflammation and related signaling pathways. -
MAO-B Inhibitor
MAO-B-IN-19 is a selective inhibitor of monoamine oxidase B (MAO-B), exhibiting an IC50 of 0.67 μM. This compound demonstrates neuroprotective effects, making it a valuable tool for research in neurodegenerative diseases. Additionally, it possesses anti-inflammatory properties, supporting its application in studying inflammation-related pathways in various biological systems. -
MAO Inhibitor
Safrazine is an irreversible, non-specific monoamine oxidase (MAO) inhibitor that is orally active. It is primarily utilized in research focused on depression and related mood disorders by modulating monoamine levels in the brain. This compound can aid in studies aimed at understanding the biochemical pathways underlying depressive states and the effects of MAO inhibition. -
MAO-B Inhibitor
MAO-B-IN-27 is a selective inhibitor of monoamine oxidase B (MAO-B), exhibiting a potent inhibitory effect with an IC50 value of 8.9 nM against human MAO-B. This compound is valuable for research applications related to neurodegenerative diseases, particularly Parkinson's disease (PD), facilitating investigations into its biochemical pathways and potential therapeutic approaches. -
MAO-B Inhibitor
MAO-B-IN-44 is a selective inhibitor of monoamine oxidase B (MAO-B), exhibiting an IC50 value of 1.01 μM while showing minimal inhibition of MAO-A (IC50 = 14.4 μM). This compound effectively reduces the degradation of neurotransmitters, particularly dopamine, making it a valuable tool for studying neurodegenerative disorders linked to MAO-B dysregulation, such as Parkinson's disease. Its selective inhibition can aid in understanding the role of MAO-B in neural pathophysiology and contribute to the development of targeted therapies. -
MAO-B Inhibitor
MAO-B-IN-29 is a selective inhibitor of monoamine oxidase B (MAO-B), a key enzyme involved in the degradation of neurotransmitters such as dopamine. This compound exhibits significant biological activity by modulating MAO-B activity, which is relevant for research into neurological disorders, including Parkinson's disease and depression. MAO-B-IN-29 serves as an important tool for studying the role of MAO-B in neurotransmitter metabolism and potential therapeutic interventions. -
hMAO-B Inhibitor
hMAO-B-IN-5 is a potent and selective reversible inhibitor of human monoamine oxidase-B (hMAO-B), exhibiting an IC50 of 120 nM and a Ki of 33 nM. This compound is valuable for studying neurodegenerative diseases, as it modulates the metabolism of neuroactive amines and has implications in the treatment of conditions such as Parkinson's disease. Researchers can utilize hMAO-B-IN-5 to explore hMAO-B's role in neurobiology and drug development. -
MAO-B Inhibitor
MAO-B-IN-15 is a selective inhibitor of monoamine oxidase B (MAO-B), with an IC50 value of 13.5 μM, demonstrating its ability to effectively inhibit enzymatic activity through π-π interactions with the Tyr 326 residue. This compound is integral for research focused on neurodegenerative disorders, particularly Parkinson's disease, by potentially enhancing dopaminergic neurotransmission and reducing oxidative stress associated with neuronal degeneration. -
MAO Inhibitor
Pivalylbenzhydrazine is a potent inhibitor of monoamine oxidase (MAO), an enzyme involved in the oxidative deamination of neurotransmitters. This compound has been shown to decrease cartilage growth in normal rats, indicating its potential influence on cellular growth processes. Pivalylbenzhydrazine is useful for research applications related to depression and other neurological conditions by modulating neurotransmitter levels. -
MAO-B Inhibitor
Monoamine Oxidase B inhibitor 2 is a selective and reversible inhibitor of monoamine oxidase B (MAO-B), demonstrating an IC50 of 1.33 nM. This compound exhibits antioxidant and anti-neuroinflammatory properties, making it valuable for research related to neurodegenerative disorders. Due to its ability to cross the blood-brain barrier, Monoamine Oxidase B inhibitor 2 is particularly useful in the study of Parkinson's disease mechanisms and potential therapeutic interventions. -
MAO-B Inhibitor
(E)-CHBO4 is a potent inhibitor of monoamine oxidase B (MAO-B), exhibiting an IC50 value of 0.023 μM. This compound is valuable for investigating the biochemical pathways involved in neurodegenerative disorders such as Parkinson's disease. Its selective inhibition of MAO-B makes it an important tool for studying the role of this enzyme in dopamine metabolism and potential therapeutic strategies. -
MAO Inhibitor
Mebanazine is a potent monoamine oxidase (MAO) inhibitor. It has shown promise in modulating monoamine levels, thus making it a valuable tool in the study of depressive disorders. Mebanazine's ability to enhance neurotransmitter availability supports research in neuropharmacology and the development of antidepressant therapies. -
Monoamine Oxidase Inhibitor
N-2-Cyclohexylethyl-N-methylamine is a monoamine oxidase inhibitor that effectively reduces the activity of the MAO enzyme. This compound is derived from A. ridigula Benth and plays a crucial role in neuromodulation. It can be utilized in research applications involving neurological disorders and the study of serotonin and dopamine metabolism. -
MAO Inhibitor
Phenoxypropazine is a potent monoamine oxidase (MAO) inhibitor that significantly modulates neurotransmitter levels in the central nervous system. This compound has demonstrated biological activity relevant to the study of depressive disorders and may aid in exploring the underlying mechanisms of mood regulation. Its role in MAO inhibition makes it a valuable tool for researchers investigating therapeutic strategies for depression and related mood disorders. -
MAO A Inhibitor
Salsolidine hydrochloride is a tetrahydroisoquinoline alkaloid that serves as a stereoselective competitive inhibitor of monoamine oxidase A (MAO A). It exhibits significant biological activity by modulating neurotransmitter levels, making it a valuable tool for research into neurodegenerative disorders and mood disorders. This compound is instrumental in exploring the therapeutic potential of MAO A inhibition in various preclinical studies. -
MAO-B Inhibitor
Monoamine Oxidase B Inhibitor 1 is a highly selective and reversible inhibitor of monoamine oxidase B (MAO-B), exhibiting an IC50 value of 0.02 nM. This compound demonstrates notable antioxidant and anti-neuroinflammatory properties. Its ability to cross the blood-brain barrier makes it a valuable tool for research applications related to neurodegenerative diseases, particularly Parkinson's disease. -
MAO-A/SERT Inhibitor
MAO-A/SERT-IN-1 is an inhibitor of monoamine oxidase A (MAO-A) and the serotonin transporter (SERT). This compound effectively reduces SERT-mediated reuptake of serotonin (5-HT), demonstrating notable neuroprotective properties in cell inhibition models. In preclinical studies, MAO-A/SERT-IN-1 has shown the ability to improve depressive behaviors in both zebrafish and murine models, making it a valuable tool for research in depression and related neuropsychiatric disorders. -
MAO A Inhibitor
Tetrindole hydrochloride is a selective inhibitor of monoamine oxidase A (MAO A) with competitive inhibitory properties, exhibiting a Ki value of 0.4 μM for rat brain mitochondrial MAO A and a Ki of 110 μM for MAO B. This compound demonstrates notable antidepressant activity, making it a valuable tool for neurological research. Its selective inhibition profile positions Tetrindole hydrochloride as a relevant reagent for investigating the biochemical pathways associated with mood disorders and the role of MAO A in neurotransmitter metabolism. -
MAO-B Inhibitor
Lazabemide hydrochloride is a selective, reversible inhibitor of monoamine oxidase B (MAO-B) with an IC50 of 0.03 μM, demonstrating minimal activity against MAO-A (IC50 > 100 μM). At elevated concentrations, it inhibits monoamine uptake, with IC50 values of 86 μM for noradrenaline, 123 μM for serotonin, and >500 μM for dopamine. This compound is primarily used in research related to Parkinson's and Alzheimer's diseases, offering insights into the management of neurodegenerative disorders. -
MAO-A Inhibitor
MAO-A-IN-2 is a selective inhibitor of monoamine oxidase A (MAO-A) with an IC50 value of 0.4 μM. By inhibiting MAO-A, this compound effectively reduces the degradation of key monoamine neurotransmitters, including serotonin and norepinephrine. MAO-A-IN-2 is valuable for research into neurological diseases associated with monoamine neurotransmitter imbalances, such as depression and anxiety disorders. -
Monoamine Oxidase Inhibitor
Iproclozide is an irreversible and selective inhibitor of monoamine oxidase, exhibiting notable antidepressant properties. This compound is utilized in research focused on depressive disorders, facilitating the study of monoamine metabolism and potential therapeutic interventions in mood regulation. Its mechanism of action provides valuable insights into the biochemical pathways associated with depression. -
hMAO-B Inhibitor
hMAO-B-IN-12 is a selective inhibitor of human monoamine oxidase B (hMAO-B), exhibiting an IC50 of 17.7 nM. This compound effectively reduces oxidative stress and diminishes lipid metabolism-derived products, such as hydrogen peroxide. hMAO-B-IN-12 is a valuable tool for studying the mechanisms underlying atherosclerosis and related metabolic disorders. -
MAO-B Inhibitor
MAO-B-IN-12 is a potent inhibitor of monoamine oxidase B (MAO-B) with an IC50 value of 1.3 μM. This compound exhibits neuroprotective activity, making it a valuable tool for research into neurodegenerative diseases and related neurological disorders. Its selective inhibition of MAO-B may contribute to the modulation of neurotransmitter levels, and it is suitable for studies focused on neuroprotection and neuronal health. -
MAO-B Inhibitor
MAO-B-IN-53 is a selective inhibitor of human monoamine oxidase B (hMAO-B) with an IC50 of 0.066 μM. This compound demonstrates mixed reversible inhibition and binding stability at the hMAO-B active site, while displaying a high selectivity for hMAO-B over hMAO-A. Due to its neuroprotective properties, MAO-B-IN-53 has been shown to mitigate 6-OHDA-induced cellular damage with minimal neurotoxicity in neuroblastoma cells, making it a valuable reagent for research into Parkinson's disease. -
Monoamine Oxidase Inhibitor
Fluoroclorgyline is a potent monoamine oxidase inhibitor that demonstrates an IC50 of 39 nM. This compound effectively modulates monoamine levels, making it a valuable tool for studying neurotransmitter dynamics and related disorders. Its application in neuropharmacology and mental health research provides insight into the biochemical pathways involved in mood regulation and neurodegenerative diseases. -
Monoamine Oxidase Inhibitor
Pimprinine is a potent monoamine oxidase inhibitor that has been isolated from fermented broths. This compound exhibits significant antioxidative properties and demonstrates anticonvulsant activity. Research indicates that Pimprinine effectively inhibits tremorine-induced tremors and produces analgesic effects in murine models, making it valuable for further investigation in neuropharmacological studies. -
MAO-B Inhibitor
PSB-1434 is a selective inhibitor of monoamine oxidase B (MAO-B), exhibiting an IC50 of 1.59 nM. This compound demonstrates greater than 6000-fold selectivity for MAO-B over MAO-A. PSB-1434 is primarily utilized in research applications focused on neurological disorders, making it a valuable reagent for studies involving dopaminergic signaling and neurodegenerative diseases. -
MAO-B inhibitor
Illudinine is a sesquiterpenoid alkaloid that acts as a selective inhibitor of monoamine oxidase B (MAO-B), exhibiting an IC50 value of 18.3 μM. This compound is valuable for investigating the biochemical pathways associated with neurological diseases, making it a potential tool for the study of neurodegenerative disorders and related therapeutic approaches. -
MAO-B Inhibitor
MAO-B-IN-42 is a selective and reversible inhibitor of monoamine oxidase-B (MAO-B), exhibiting an IC50 value of 0.184 μM. By inhibiting the oxidative deamination of monoamines, MAO-B-IN-42 helps preserve neurotransmitter levels. This compound is valuable for research in Parkinson's disease and related neurological conditions. -
hMAO-B Inhibitor
hMAO-B-IN-3 is a potent inhibitor of human monoamine oxidase B (hMAO-B) with an IC50 value of 47.4 nM. This compound exhibits favorable agent-like properties and a broad safety margin, making it an excellent candidate for lead optimization. Its activity suggests potential applications in the development of multitarget-directed ligands for neurodegenerative diseases and related research areas. -
MAO-B Ligand
FCOB02 is a potent monoamine oxidase B (MAO-B) ligand designed for imaging applications. It exhibits high affinity for MAO-B, with an IC50 value of 10.68 nM, making it suitable for in vivo studies. When labeled as [18F]FCOB02, it serves as a valuable probe for specific MAO-B imaging and quantitative analysis, enabling researchers to investigate the role of MAO-B in various biological processes and diseases. -
Insecticides/Monoamine Oxidase Inhibitors
Insecticidal Agent 32 is a potent insecticide and monoamine oxidase inhibitor that targets the enzyme responsible for the degradation of neurotransmitters in insects. This compound exhibits significant biological activity by disrupting normal neurological functions, leading to increased toxicity in target insect species. It is valuable in research applications focusing on insect neurobiology and the development of innovative pest control strategies. -
MAO-A/B Inhibitor
WAY-620147 is an N-(2-morpholinoethyl)nicotinamide derivative that acts as a selective inhibitor of monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B). Demonstrating inhibitory potency with IC50 values of 26 μM for MAO-A and 55 μM for MAO-B, this compound is valuable for exploring the roles of these enzymes in neurochemistry and the treatment of mood disorders. Research applications include studying monoamine metabolism and the potential development of antidepressant therapies. -
Monoamine Oxidase-A Inhibitor
BW1370U87 is a selective inhibitor of monoamine oxidase-A (MAO-A), a key enzyme involved in the catabolism of monoamines. This compound exhibits anti-depressant activity, making it a valuable tool for research focused on mood disorders and neuropharmacology. Its ability to modulate neurotransmitter levels positions BW1370U87 as a candidate for studying therapeutic strategies targeting depressive and anxiety-related conditions. -
MAO Inhibitor
6-Acetonyl-N-methyldihydrodecarine is a natural alkaloid recognized for its function as a monoamine oxidase (MAO) inhibitor. This compound exhibits significant biological activity by modulating the levels of monoamines, which are crucial neurotransmitters in various physiological processes. It serves as a valuable reagent in research applications targeting neuropharmacology and the study of mood disorders. -
MAO-B Inhibitor
NW-1172 free base is a selective inhibitor of monoamine oxidase B (MAO-B). It demonstrates significant biological activity by increasing levels of neurotransmitters, making it useful in research applications related to neurodegenerative disorders and mental health. Studies indicate that the (R) isomer is more effective than the (S) isomer, showing superior performance in cognitive tasks and enhanced affinity for the MAO-B target, thus providing insights into its potential therapeutic benefits. -
MAO-B Inhibitor
PSB-1410 is a selective and competitive inhibitor of monoamine oxidase B (MAO-B), exhibiting an IC50 value of 0.23 nM for human MAO-B and 1.01 nM for rat MAO-B. Its potent inhibition of MAO-B activity makes PSB-1410 valuable for research into neurodegenerative diseases, mood disorders, and other conditions associated with altered monoamine levels. This compound is suitable for studies focusing on the modulation of neurotransmitter metabolism and the role of MAO-B in various biological processes. -
MAO-B Inhibitor
SZV-558 is a selective inhibitor of monoamine oxidase B (MAO-B), demonstrating IC50 values of 50 nM for rat and 60 nM for human MAO-B. This compound has potential applications in the study of Parkinson's disease models, providing insights into neurochemical pathways and therapeutic strategies for this neurodegenerative disorder. Its potency makes it a valuable tool for research focused on MAO-B-related mechanisms in neurodegeneration. -
MAO-B Inhibitor
NW-1772 (methanesulfonate) is a selective inhibitor of monoamine oxidase B (MAO-B), demonstrating potent reversible inhibition. It is characterized by its ability to rapidly penetrate the blood-brain barrier, short-acting effects, and minimal toxicity in vitro. Additionally, NW-1772 shows limited inhibition of certain cytochrome P450 enzymes, making it a valuable tool for investigating neurodegenerative diseases and exploring the biochemical pathways related to neurotransmitter metabolism. -
Monoamine Oxidase Inhibitor
Lilly 51641 is a selective and orally active inhibitor of Type A monoamine oxidase, influencing neurotransmitter metabolism. This compound exhibits potential for investigation in neurological disorders, particularly depression and schizophrenia, by modulating levels of norepinephrine and serotonin. Its targeted mechanism makes it a valuable tool for research into the underlying biochemical pathways of these conditions. -
hMAO-A Inhibitor
hMAO-A-IN-1 is a selective inhibitor of human monoamine oxidase A (hMAO-A), exhibiting a potency with an IC50 of 90 nM. This compound is suitable for investigating the role of hMAO-A in neuropsychiatric disorders, particularly in the context of anxiety and depression research. Its inhibition of hMAO-A provides valuable insights into monoamine metabolism and its implications in mental health. -
MAO Inhibitor
5-(2-Aminopropyl)indole is a potent monoamine oxidase (MAO) inhibitor that exhibits psychoactive properties. This compound demonstrates long-lasting stimulatory effects, making it relevant for studies investigating neurotransmitter modulation and related behavioral outcomes. Its applications include research into mood disorders, neurodegeneration, and the pharmacological mechanisms underlying psychoactive substances. -
MAO-A Inhibitor
Brofaromine hydrochloride is a selective inhibitor of monoamine oxidase A (MAO-A), as well as a 5-hydroxytryptamine (5-HT) uptake inhibitor. This compound exhibits significant antidepressant-like effects, demonstrated in preclinical models, including the social conflict test in rodents. It is primarily used in research examining mood disorders and the pharmacological modulation of serotonin levels. -
MAO-B Inhibitor
Atibeprone is a selective inhibitor of monoamine oxidase B (MAO-B), a key enzyme involved in the metabolism of neurotransmitters. This compound exhibits notable antidepressant activity, making it relevant for research into mood disorders and neurodegenerative diseases. Its specificity for MAO-B allows for the potential exploration of therapeutic strategies with reduced side effects compared to non-selective MAO inhibitors.
